Dermatology specialist, LEO Pharma, has announced that the European Commission (EC) has granted marketing authorisation for its new biologic, Kyntheum (brodalumab), for the treatment of moderate-to-severe plaque psoriasis in adults within the EU who are candidates for systemic therapy.
Authorised
Kyntheum specifically binds to the receptor on skin cells rather than targeting free floating inflammatory mediators — which differentiates it from other existing therapies — and blocks the biological activity of several pro-inflammatory IL-17 cytokines involved in psoriasis plaque formation.
“Lasting skin clearance is our ultimate treatment goal for psoriasis patients, as it has such a significant impact on an individual’s wider wellbeing, along with their physical health. Experiencing clear skin brings a huge benefit to patients,” commented Professor Dr Ulrich Mrowietz, Psoriasis Centre, University Medical Centre, Schleswig-Holstein, Germany.
Gitte Pugholm Aabo, president and CEO of LEO Pharma, said: “Those most affected by psoriasis often feel controlled by their condition, the stigma it brings, and the diverse complications associated with it. We hope that the EU approval of Kyntheum will help many more people to regain control, and live lives unrestricted by psoriasis, while our role is to support them throughout their journey to clear skin.”